IL5 and asthma: Previous work re-analyzing existing licensing-trial data comparing the efficacy of anti-IL5 and anti-IL5Rα biologics led to conflicting results, observing either no differences or and advantage of mepolizumab in improving asthma control and exacerbation reduction.